New Pharmaceutical & Safety Trademark Report Now Available

We are pleased to inform you that our office now has access to a brand new Pharmaceutical and Name Safety Trademark Search Report. This new report is a unique Pharmaceutical Research Report that meets the demanding needs of the pharmaceutical trademark professional.

At this time, our search provider is the only company that includes POCA (Phonetic Orthographic Computer Analysis) in every pharmaceutical search. POCA is a powerful phonetic and orthographic algorithm developed and made available by the FDA to help identify drug and biologic names and medical terminology that are phonetically and orthographically similar to one another and provides a percentage ranking based on similarity of the names. See http://www.thefederalregister.com/d.p/2009-02-17-E9-3170. The FDA uses POCA as part of its evaluation process. Using POCA in the trademark clearance process will permit trademark attorneys and name safety specialists to be more objective in their analysis of existing names and to predict with greater success whether or not a drug name will be approved by the FDA.

Other key features of this exclusive report and support the FDA PDUFA 1V Pilot Project are:

• FDA Orange Book records are now in a composite format – Combining products under a brand name and new drug application (NDA) into a single full record including POCA the score.
• Provides key Pharma In-Use information for a quick overview of all jurisdictions cited for a particular mark, while showing the depth of use of the mark globally.
• Name Safety Section contains Drugs@FDA, AERS (Adverse Events Reporting System), VAERS (Vaccine Adverse Events Reporting System).
• USAN Names and Stems – This new section consists of USAN names that fills in the currency gap with the USP Dictionary and checks for occurrences of USAN stems anywhere in the mark.
• New Pharmaceutical industry specific investigative tools – Provides visual images of capsules and tablets along with the drug name and drug strength.

In addition to the above regulatory information, the format of the report has been changed to include a graphic overview of cited marks showing where it fall across all sections, avoiding “flipping” through various common law sections to collect pertinent information.

If you have any questions about this new report, please let us know.

Leave a Reply